



May 8th & 9th



Micro Lab General Contamination Control and Personnel Training

Josh Eaton Senior Director, Scientific and Regulatory Affairs PDA



May 8th & 9th



Introductions

- MS in Biotechnology from Georgetown University
- Background in protein chemistry and separation science
 - Made drug discovery and research reagents
- First job was researching *Pseudomonas aeruginosa*

- S&RA department in PDA is the conduit for all:
 - Technical Reports
 - Points to Consider
 - Standards
 - Interest Groups
 - Technical Advisory Boards



May 8th & 9th



On the Docket



- Contamination Control Considerations
- Training Requirements and Strategies
- PDA and Industry Resources



May 8th & 9th





What do Micro Labs do?

- Sterility testing
- Detection, isolation, enumeration and identification of microorganisms (bacteria, yeast and molds) and testing for bacterial endotoxins in different materials (e.g., starting materials, water), products, surfaces, garments and the environment
- Assay using microorganisms as part of the test system

Midwest Chap

May 8th & 9th





May 8th & 9th



How to get it done:

Control Control Strategy/ Policies

Trained Operators/ Analysts

Micro Lab Operations



May 8th & 9th



The Contamination Control Strategy (CSS)

- Why?
- What's it about?
- How does it happen?



May 8th & 9th



Holistic CCS

Holistic CCS is a major principle of the EU Annex 1 revision

"2.4 <u>Contamination control and steps taken to minimize the risk of</u> contamination <u>from microbial, endotoxin/pyrogen and particle sources</u> includes a <u>series of interrelated events and measures</u>.

These are typically assessed, controlled and monitored individually but their collective effectiveness should be considered together."

- 2022 EMA Annex 1



May 8th & 9th



Building the CSS Structure





May 8th & 9th

CCS Overview



Technical Report No. 90

Contamination Control Strategy Development in Pharmaceutical Manufacturing

- Holistic CCS
- Practical Considerations > Template for CCS

Case StudyTemplate for CCS







May 8th & 9th



Practical Considerations for CCS



Laboratory Facility

- Storage of Materials and Equipment
- Materials, Equipment, or Waste
- Movement and Gowning of Personnel



Maintenance

- Training of Maintenance Personnel
- Protection of Environment and Equipment during Maintenance
- Cleanup and Return to Service



Raw Materials/ Consumables

- Adventitious agents
- Vendor defects



May 8th & 9th



Practical Considerations for CCS





May 8th & 9th



Process Constructing **Knowledge** the CCS **Technical** Knowledge CSS QRM Assessment Personnel and Quality Culture



May 8th & 9th



Process Knowledge





May 8th & 9th



Technical Knowledge

Understanding <u>how</u> to prevent contamination

Microbial behavior and biofilm development	Equipment design principles
Aseptic processing	Cleaning, disinfection, decontamination, sanitization, sterilization principles
Viral behavior and host infection	Raw material quality
Process design principles	Quality Risk Management principles

Facility and utility design principles



May 8th & 9th



Use available knowledge – Don't reinvent the wheel!

ICH Quality Guideline Q7A: Good Manufacturing PDA Technical Report No. 41 (rev. 2008): Virus Filtration, Practice Guidance for Active Pharmaceutical Technical Report No. 42: Process Validation of Protein Ingredients Manufacturing, Technical Report No. 44: Quality Risk Management for Aseptic Processes, Technical Report No. 45: PDA Points to Consider 1 Aseptic Processing Filtration of Liquids Using Cellulose-Based Depth Filters, *Technical Report No. 83: Virus Contamination in* Technical Report No. 60: Process Validation: A Lifecycle *inufacturing: Risk Mitigation, Preparedness and Response* Approach, Technical Report No. 81: Cell-Based Therapy Control Strategy PDA Technical Report No. 26 (Rev. 2008). Sterilizing Filtration of Biotechnology Manufacturing Operations, ICH *Quality Guideline Q9: Quality Risk Management* ISPE Baseline Guide: Volume 3 – Sterile Product Manufacturing Liquids. Facilities, PDA Points to Consider for Aging Facilities for Clea ms: Design, Commissioning, Operation, PDA Technical Report No. 34: Design and Validation of Isolator nd Maintenance, Technical Report No. 49: Points Systems for the Manufacturing and Testing of Health Care Biotechnology Cleaning Validation, Technical Products, PDA Points to Consider for the Aseptic Processing of Steam In Place, Technical Report No. 70: Pharmaceutical Products in Isolators of Cleaning and Disinfection Programs for Aseptic

Manufacturing Facilities,



May 8th & 9th

Quality Risk Management Assessment



Is the lab designed properly?



Where are the manual and the automated steps?



Can standardized practices from other parts of the organization be applied?



Are new contamination control technologies and procedures being implemented?



The CCS should be designed with redundant individual control elements so that <u>no single failure</u> in one element <u>will result in</u> contamination.

18



May 8th & 9th



Personnel Awareness and Quality Culture

Contamination control should be a priority reflected in the goals of the firm Ongoing campaign to promote contamination control awareness

A dedicated champion or team should oversee the CCS performance

One-time or annual training does not ensure ongoing awareness



May 8th & 9th



Personnel Awareness and Quality Culture

Hallmarks of a robust quality culture that promotes contamination control:	Focus on prevention
	Willingness to improve
	Strong response to contamination events
	Management support and recognition
	Strong, supportive communities of practice
	Employees who feel ownership over product quality
	Employees who understand their responsibilities
	Non-blaming culture



May 8th & 9th

Personnel Awareness and Quality Culture



Personnel awareness is achieved through training, education, and ongoing diligence



Training addresses what a task is and how it is done



Education addresses why it is done

May 8th & 9th





May 8th & 9th

Training Expectations

- "Training in current good manufacturing practice shall be conducted by qualified individuals on a continuing basis and with sufficient frequency to assure that employees remain familiar with current Good Manufacturing Practices (GMP) requirements applicable to them." (CFR 21:211)
- "Microbiological test results represent one of the most difficult areas for the evaluation and interpretation of data. These evaluations require extensive training and experience in microbiology." (FDA, 1993)
- "Good manufacturing proactive regulations require an active training program and the documented evaluation of the training of analysts."(FDA, 1993)

Where to start?



May 8th & 9th



Micro Team: Assemble

Laboratory Management





Microbiology

SMEs

Microbiology Trainers



24



May 8th & 9th



Micro Team: Assemble

Laboratory Management



- Selects the team
- Approves the program
- Reviews audits and operations



May 8th & 9th



Micro Team: Assemble

Microbiology SMEs



- Provides deep knowledge
- Leads development of training/ assessments program
- Oversight/ monitoring of training program



May 8th & 9th



Micro Team: Assemble

Microbiology Trainers



- Experienced operators/analysts
 - Command/understanding of the material
 - Passion/knack for training
 - Effective communicator
 - Personable



May 8th & 9th



Micro Team in Action

- Results are in line with specs
- Operators are efficient and proficient
- Everything is on track





May 8th & 9th



Micro Team Inaction



Until it isn't



May 8th & 9th







May 8th & 9th



Training More vs Training Right





May 8th & 9th



Training Right

- Be specific
- Assume nothing
- Teach your method/process in detail
- Explain the what <u>AND</u> the why
- Use a variety of training methods
- Involve the learner
- Confirm comprehension





May 8th & 9th

PDA Resources and References

- **TR 13** Fundamentals of an Environmental Monitoring Program
- **TR 13-2** Fundamentals of an Environmental Monitoring Program Annex 1: Environmental Monitoring of Facilities Manufacturing Low Bioburden Products
- **TR 33** Evaluation, Validation and Implementation of Alternative and Rapid Microbiological Methods
- TR 54 Series on Quality Risk Management
- TR 82 Low Endotoxin Recovery
- **TR 88** Microbial Data Deviation Investigations in the Pharmaceutical Industry





May 8th & 9th



PDA Training Opportunities

- PDA 100 Aseptic Processing
- PDA 102.3 Technical Report No. 13: Fundamentals of an Environmental Monitoring Program
- PDA 247 Fundamentals of Contamination Control, Cleaning and Disinfection Programs for Aseptic Manufacturing Facilities
- PDA 612 Analysis of Environmental Monitoring Data with Respect to cGMP and Data Integrity Guidelines
- PDA 620 Technical Report No. 88 Microbial Data Deviation Investigations in the Pharmaceutical Industry



May 8th & 9th



Industry Resources and References

- USP <1117> Microbiological Laboratory Best Practices
- USP <1116> Microbiological Control and Monitoring of Aseptic Processing Environments
- USP <1113> Microbiological Characterization, Identification, and Strain Typing
- WHO TRS 961 Annex 2: Good Practices for Pharmaceutical Microbiology Laboratories



May 8th & 9th



Take home messages

- Use your team
- Take advantage of existing resources
- Be critical of your existing processes and procedures
- Change things that aren't working



May 8th & 9th



Thank you!

Josh Eaton Senior Director, Scientific and Regulatory Affairs Parenteral Drug Association® (PDA) Bethesda Towers, Suite 600 4350 East-West Highway Bethesda , MD 20814 USA

Tel: 571.895.4925 E-mail: <u>eaton@pda.org</u>